The University of Colorado Boulder signs option agreement with Nanoly Bioscience for vaccine protection technology.

Life sciences startup Nanoly Bioscience has entered into an option agreement with the University of Colorado Boulder to develop a technique for delivering vaccines to rural and underdeveloped areas of the world.

Vaccines used to treat conditions such as measles, tetanus, polio and others have to be kept cool during transportation and storage – around the 2 – 8 degrees centigrade region – to avoid degradation. This can prove especially tricky in areas where electricity is in short supply.

To counteract this, a team from the university have developed a nano-polymer material which can be customised and blended with a vaccine to keep it cool, ultimately leading to wider availability of vaccines.

Mary Beth Vellequette, director of technology transfer for CU-Boulder, said: “We are excited that Nanoly has optioned Dr. Anseth’s polymer technology. Nanoly has a very dynamic team that is passionate about developing this technology and we are eager to continue working with them as this venture grows.”